New Product Update: Baorui circRNA Series -circRNA Separation Pre-Prepared Gel Kit

In the field of nucleic acid drugs, research on circRNA (circular RNA) is becoming a highly sought-after focus. circRNA, with its unique closed circular structure, demonstrates outstanding stability compared to traditional linear RNA. It can effectively resist the degradation of exonucidases and exert a long-lasting effect within cells.

In January 2025, HM2002 Injection, a circular RNA drug independently developed by Shanghai Huanma Biomedical Co., LTD., officially obtained the clinical trial approval (IND) from the National Medical Products Administration (NMPA) of China, becoming the first circular RNA biological product in the country to receive this approval. Before this, in October 2024, HM2002 injection of Huanma Biotech was approved by the US Food and Drug Administration (FDA), becoming the world's first circular RNA therapy to be permitted by the FDA to enter clinical trials and also the world's first circular RNA drug to receive regulatory approval from both China and the United States to enter the clinical stage. This series of approval achievements demonstrate the huge potential and feasibility of circRNA in the field of drug research and development, and also indicate that the era of circRNA drugs is accelerating its arrival.

According to research data from Nova One Advisor, the global circRNA market size exceeded 184 million US dollars in 2024 and is expected to exceed 805 million US dollars by 2034, with a compound annual growth rate as high as 15.89% from 2025 to 2034.

The artificial synthesis of circRNA involves multiple steps. During this process, in addition to the target circRNA, many other products are usually generated, such as linear Precursor RNA (preRNA for short hereinafter), dropped introns, Nicked RNA, etc. At present, the main methods for separation and identification include two aspects: liquid chromatography and electrophoresis. Although chromatographic technology is relatively precise in the separation of circRNA, various limiting factors make it impossible for liquid-phase technology to achieve rapid and efficient separation under conditions such as system, chromatographic column, and flow equality screening.

In contrast, electrophoresis technology has become the preferred choice for identifying circrnas due to its simplicity and high efficiency. At present, there are no targeted electrophoresis products related to circRNA identification on the market. Therefore, the universal agarose electrophoresis has become the first choice for many researchers in the field of circRNA.

Figure 1: Laboratory-prepared agarose gel electrophoresis for the isolation and identification of circRNA

As shown in Figure 3, when dealing with artificially synthesized circRNA samples, multiple target bands can be clearly separated in an extremely short time, greatly enhancing the experimental efficiency and data quality.

Table 1: Components of circRNA Isolation Pre-prepared Gel Kit (BP-S03-10)

This kit contains the corresponding reagents for circRNA electrophoresis identification and analysis. Currently, there are no similar products in the domestic and international markets. The circRNA isolation pre-prepared gel kit from Baorui Biotech fills this gap and provides researchers with an unprecedentedly powerful tool.

Whether it is the basic research in universities and research institutes or the drug development in biopharmaceutical enterprises, this pre-prepared adhesive will play a key role in circrNA-related experiments. In basic research, it helps researchers more accurately analyze the structure and function of circRNA and deeply explore its mechanism of action in organisms. In the field of drug research and development, it can be used for the purity detection, quality control and efficacy evaluation of circRNA drugs, accelerating the research and development process of new drugs.

In terms of circRNA synthesis, to adapt to different scenarios and meet various demands, Baorui Biotech has developed multiple systems for circRNA production. Its self-produced GMP-level RNase R for digesting linear RNA has been filed with the DMF. The entire product line together has created a complete product line for circRNA from production to detection. We look forward to working hand in hand with researchers at home and abroad to jointly promote the industrial breakthrough and development of circRNA technology.

For new product inquiries, please scan the code